Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
Prediction of the clinical outcome of breast cancer is multi-faceted and challenging. There is growing evidence that the complexity of the tumour micro-environment, consisting of several cell types and a complex mixture of proteins, plays an important role in development, progression, and response to therapy. In the current study, we investigated whether invasive breast tumours can be classified on the basis of the expression of extracellular matrix (ECM) components and whether such classification is representative of different clinical outcomes. We first examined the matrix composition of 28 primary breast carcinomas by morphology and gene expression profiling using 22K oligonucleotide Agilent microarrays. Hierarchical clustering of the gene expression profile of 278 ECM-related genes derived from the literature divided the tumours into four main groups (ECM1-4). A set of selected differentially expressed genes was validated by immunohistochemistry. The robustness of the ECM classification was confirmed by studying the four ECM groups in a previously published gene expression data set of 114 early-stage primary breast carcinomas profiled using cDNA arrays. Univariate survival analysis showed significant differences in clinical outcome among the various ECM subclasses. One set of tumours, designated ECM4, had a favourable outcome and was defined by the overexpression of a set of protease inhibitors belonging to the serpin family, while tumours with an ECM1 signature had a poorer prognosis and showed high expression of integrins and metallopeptidases, and low expression of several laminin chains. Furthermore, we identified three surrogate markers of ECM1 tumours: MARCO, PUNC, and SPARC, whose expression levels were associated with breast cancer survival and risk of recurrence. Our findings suggest that primary breast tumours can be classified based upon ECM composition and that this classification provides relevant information on the biology of breast carcinomas, further supporting the hypothesis that clinical outcome is strongly related to stromal characteristics.
Bergamaschi
A
A
Department of Genetics, Institute for Cancer Research, Rikshospitalet-Radiumhospitalet Medical Centre, Montebello, Oslo, Norway.
Tagliabue
E
E
Sørlie
T
T
Naume
B
B
Triulzi
T
T
Orlandi
R
R
Russnes
H G
HG
Nesland
J M
JM
Tammi
R
R
Auvinen
P
P
Kosma
V-M
VM
Ménard
S
S
Børresen-Dale
A-L
AL
D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000145:classification* / Q000235:genetics; D015816:Cell Adhesion Molecules, Neuronal / Q000235:genetics; D016326:Extracellular Matrix Proteins / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D007150:Immunohistochemistry; D020411:Oligonucleotide Array Sequence Analysis; D015676:Osteonectin / Q000235:genetics; D011379:Prognosis; D011971:Receptors, Immunologic / Q000235:genetics; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; C527430:IGDCC3 protein, human; D007136:Immunoglobulins; C490460:MARCO protein, human; D015676:Osteonectin; D011971:Receptors, Immunologic